INTRODUCTION
Metabolic adaptations defend cellular, tissue, and systemic homeostasis. However, chronic exposures to rapid nutrient flux predispose cells to nutrient accumulation, which can stress adaptive systems and cause a cluster of metabolic diseases (Hotamisligil, 2017) . The endoplasmic reticulum (ER) is an adaptive organelle that defends homeostasis by operating as a platform for enzymes that couple nutrient-derived cues, substrates, or stress signals with coordinated changes in protein synthesis, folding, and secretion as well as lipid metabolism and trafficking (Fu et al., 2012; Goldstein et al., 2006; Ron and Walter, 2007; Russell, 2003) . These functions require membrane-spanning stress sensors such as those mediating the unfolded protein response (UPR) or the sterol response element binding protein 2 (SREBP2) sterol-sensing complex, which engage metabolic and inflammatory (metaflammatory) outputs to restore homeostasis.
Targeting these systems holds great therapeutic promise, and more opportunities will likely emerge upon identifying the complete spectrum of ER adaptive systems, and how they are integrated during metabolic stress.
Exposure to excess dietary cholesterol or increased circulating cholesterol is pathogenic in diabetes, fatty liver disease, neurodegeneration, and atherosclerosis. The ER coordinates the metabolism of excess cholesterol through esterification, oxysterol formation, or conversion into bile (Chang et al., 2006; Russell, 2003) . This offsets the volatility of rising cholesterol but requires tight constraints as the entire cholesterol pool rapidly cycles through the ER, and, when cellular thresholds are surpassed, much of the excess is deposited in the ER membrane (Lange et al., 2014; Steck and Lange, 2010) . However, the ER has an extremely low cholesterol carrying capacity amounting to only 1% of cellular levels (Radhakrishnan et al., 2008; Steck and Lange, 2010) . Hence, without a strong adaptive response, a rise in cholesterol flux would alter ER membrane fluidity and disrupt the activity of ER membrane-embedded enzymes (Fu et al., 2012; Maxfield and Tabas, 2005) , resulting in impaired cellular function and survival.
As guarding against cholesterol toxicity is necessary to sustain metabolism, the ER must adapt to cholesterol excess. Factors mediating this adaptation are not well understood. One factor is acyl-coenzyme A: cholesterol acyltransferase (ACAT), which detoxifies cholesterol by forming cholesterol esters (Chang et al., 2006) . However, this strategy has limitations since ACAT does not eliminate but rather stores cholesterol, which must at some point reenter the cellular pool. Moreover, ACAT is dispensable in cholesterol challenged phagocytes (Cui et al., 2007) , and ACAT inhibition does not exhibit pathogenic effects in models of atherosclerosis (Ló pez-Farré et al., 2008) . Thus, the protective role of ACAT appears to be conditional. Other adaptive factors are liver X receptors (LXRs), which drive cholesterol export (Bensinger and Tontonoz, 2008) . However, LXRs do not bind cholesterol and are constitutively bound to genomic DNA (Watanabe et al., 2003) ; thus, it is difficult to conceive how LXR senses cholesterol within the ER to ensure an effective adaptation. Given the unique vulnerabilities of the ER to cholesterol, we predicted the existence of an ER cholesterol sensor that mediates an adaptive response guarding against excess cholesterol exposure.
Upon considering the structural (recognize cholesterol), spatial (reside in ER), and functional (mitigate stress) properties such a factor might possess, we identified nuclear factor erythroid 2 related factor-1 (Nrf1; also known as Nfe2L1) as a potential candidate. Nrf1 is a ubiquitously expressed ER-membrane spanning protein belonging to the Cap'N'Collar (CNC) family of transcription factors that are involved in stress adaptation and detoxification (Sykiotis and Bohmann, 2010) . Though newly synthesized Nrf1 is ER membrane bound, cleavage near the N terminus releases Nrf1 from the ER to regulate transcription through anti-oxidant response elements (AREs) in the genome (Radhakrishnan et al., 2014) . However, physiological stimuli regulating Nrf1 remain enigmatic. Particularly interesting to us was Nrf1 features cholesterol recognition amino acid consensus (CRAC) domains (Zhang et al., 2014) that could render Nrf1 a cholesterol sensor. This raised the possibility that the ER localization and evolutionary function of Nrf1 in stress adaptation might play a role in cholesterol metabolism. Here, we demonstrate that Nrf1 is an ER cholesterol sensor coupled to an adaptive response defending against cholesterol accumulation.
RESULTS

Identification of a Link between Nrf1, Cholesterol, and Stress Resistance
The mechanisms by which the ER averts cholesterol toxicity are poorly understood. We reasoned that if Nrf1 contributed to this biology, its level or activity might be regulated by excess cholesterol exposure. Indeed, while several ER-modifying or stress-inducing agents were unable to regulate Nrf1 expression, cholesterol treatment robustly increased Nrf1 protein level in Hepa 1-6 cells, as well as in primary mouse embryonic fibroblasts (MEFs), and, in either cell type, this occurred independent of a change in Nrf1 mRNA levels (Figures 1A and S1A-S1D). In contrast, Nrf2, the cytosolic homolog of Nrf1, was not regulated by cholesterol. Interestingly, the accumulation of Nrf1 protein was specific to the uncleaved full-length form, comprising the glycosylated and unglycosylated protein. This differed from the response of Nrf1 to proteasome inhibitor epoxomycin, which increased the level of the deglycosylated and cleaved 95 kDA form of Nrf1, in agreement with a previous report (Radhakrishnan et al., 2014) . To confirm the effect of cholesterol on Nrf1 in vivo, we fed lean mice a cholesterol-enriched diet (Chol-Diet) that promotes hypercholesterolemia and hepatic cholesterol accumulation and found that just 1 day of this challenge was sufficient to increase Nrf1 protein level in liver, without altering its mRNA levels ( Figures 1B and S1E ). These results show that Nrf1 exhibits a specific and unique response to excess cholesterol exposure.
To examine the role of this response, we next established a model of Nrf1 deficiency. We took advantage of genetic systems from the international mouse phenotyping consortium to produce a germline nonsense mutation, from which we could restore a functional allele with the potential for a conditional deletion. We generated isogenic Nrf1-deficient (Nrf1 À/À ) and Figure 1C ), a stress-activated kinase. Though embryonic lethality prevented the study of mice with global Nrf1 deficiency, 1 week of Chol-Diet feeding increased JNK phosphorylation in livers of Nrf1 haploinsufficient (Nrf1 +/À ) mice compared to Nrf1 +/+ controls ( Figure S1G ), suggesting Nrf1 may mitigate cholesterol-induced stress. To establish the role of hepatocyte Nrf1 in managing the stress of excess cholesterol, we generated mice with loxP sites spanning exons 4 and 5 of Nfe2l1 (Nrf1  flox ) and bred them to mice expressing albumin-promoter driven Cre-recombinase, resulting in mice with hepatocyte-specific Nrf1 deficiency (Nrf1 L-KO ). Nrf1 flox and Nrf1 L-KO mice were fed regular diet (Reg-Diet) or Chol-Diet for 1-4 weeks, and then liver tissue was collected. In contrast to control mice, Chol-Diet-fed Nrf1 L-KO mice developed dramatic liver discoloration ( Figure 1D ) and increased liver weight, despite not having increased body weight (Figures 1E and S1H) , and H&E staining showed massive lipid accumulation and indications of hepatocyte ballooning and damage ( Figure 1F ). Overall, these data reveal a critical physiological role for hepatocyte Nrf1 in protecting the liver from cholesterol excess.
We next investigated the role of Nrf1 on hepatic lipid profiles. Using livers from Nrf1 flox and Nrf1 L-KO mice fed a high cholesterol or control diet for 4 weeks, we systematically quantified all major classes of complex lipids. Livers from mice fed Chol-Diet, irrespective of genotype, exhibited a substantial rise in cholesterol esters accounting for more than 50% of total lipid ( Figure S2A ). The abundance of each class was not different between genotypes in mice on control diet. However, upon cholesterol exposure livers from Nrf1 L-KO mice had an elevated presence of cholesterol, cholesterol ester, and cardiolipin, whereas all other classes were unchanged (Figures 2A and S2B ). This coincided with greater cholesterol to phospholipid ratios in livers from Nrf1 L-KO mice ( Figure 2B ). To determine whether these differences occurred following acute challenges, we compared cholesterol levels in livers of Nrf1 L-KO mice to those of Nrf1 flox mice after only 2 days of exposure to a cholesterol challenge, followed by 2 days of Reg-Diet (Chol-to-Reg). Even this brief challenge resulted in elevated cholesterol and cholesterol esters in livers from Nrf1 L-KO mice, which remained elevated in the Chol-to-Reg phase ( Figure 2C ). Overall, these data indicate the constraining mechanisms limiting cholesterol accumulation are defective in Nrf1 deficiency. Since Nrf1 is expressed ubiquitously, we evaluated whether Nrf1 has a similar role on cholesterol in cells not as specialized as hepatocytes. Using primary MEFs, we quantified all major lipid classes collected from Nrf1 +/+ and Nrf1 À/À cells treated with regular media or cholesterol-enriched media overnight, or cholesterol-enriched media followed by a 6-hr Chol-to-Reg phase in regular media. As expected, cholesterol-enriched media increased cholesterol and cholesterol ester levels as well as the cholesterol to phospholipid ratio, and this was equivalent in Nrf1 +/+ and Nrf1 À/À cells ( Figures 2D and S2C ). In cells provided Chol-to-Reg, cholesterol esters were comparably elevated in both genotypes, whereas the levels of cholesterol in Nrf1
+/+ cells were almost normal, as was the ratio of cholesterol to phospholipids. However, cholesterol and the cholesterol to phospholipid ratio were elevated in Nrf1 À/À cells. Thus, in distinct cell types-fibroblasts and hepatocytes-Nrf1 is required to defend homeostatic levels of cholesterol, which, in excess, is known to have high chemical reactivity and toxicity (Steck and Lange, 2010) and to underlie the fatty liver disease non-alcoholic steatohepatitis (Ioannou, 2016) . As elevated cholesterol in livers of Nrf1 L-KO mice could be a collateral effect of prolonged hepatic Nrf1 deficiency, we examined whether we could restore the hepatic cholesterol levels of Nrf1 L-KO mice by exogenously introducing Nrf1 (Ad-Nrf1) into these animals using adenoviral delivery ( Figure 2E ). As expected, cholesterol and cholesterol ester levels were unchanged in livers of mice on control diet. However, cholesterol and cholesterolester levels in Chol-Diet-fed Nrf1 L-KO mice transduced with AdNrf1 were comparable to that of Nrf1 flox mice and less than that of Chol-Diet-fed Nrf1 L-KO mice transduced with a control adenovirus expressing b-galactosidase (LacZ). Collectively, these data strongly indicate that Nrf1 controls an adaptive process, which constrains cholesterol accumulation in vivo.
Cholesterol Regulates Nrf1 Localization, Processing, and Transcriptional Activity We showed that cholesterol regulates Nrf1 abundance, and that Nrf1 defends against cholesterol accumulation. But whether these phenomena were mechanistically linked was unclear. To explore this question, we examined how cholesterol affects Nrf1 localization, processing, and turnover. Nrf1 localization was first examined by immunofluorescence confocal imaging (F) H&E-stained liver sections (403 magnification). Data in graphs are mean ± SEM. AU, arbitrary units; FL., full length; CL., cleaved; cm, centimeter; h, hours. See also Figure S1 .
of hemagglutinin (HA)-tagged Nrf1 (Nrf1-HA) expressed in Hepa 1-6 cells ( Figure 3A ). In vehicle-treated cells, Nrf1-HA was localized at the ER and in the nucleus. However, upon cholesterol exposure Nrf1-HA was almost exclusively ER localized, and cholesterol treatment was potent enough to suppress nuclear translocation of Nrf1 in cells co-treated with the proteasome inhibitor epoxomycin. As a complementary investigation, we examined Nrf1 localization via cellular fractionation of the nucleus and cytoplasm ( Figure 3B ), in which case cholesterol reduced the cleaved, nuclear form of Nrf1 and increased the full-length, cytoplasmic form of Nrf1. To examine how cholesterol affects Nrf1 processing, we treated Hepa 1-6 cells with or without cholesterol in the presence of epoxomycin and collected lysates after 0-8 hr ( Figure 3C ). Immunoblot analysis revealed that the epoxomycin-induced rise in cleaved Nrf1 was attenuated by cholesterol. Since Nrf1 undergoes rapid proteasomemediated degradation (Biswas et al., 2011) , we examined whether cholesterol affects Nrf1 turnover by treating primary 
(legend continued on next page)
MEFs with cholesterol or vehicle for 2 hr, after which 20 mg/mL of cycloheximide (CHX) was added to block new protein synthesis and lysates collected after 0-60 min ( Figure 3D ). To ensure the general process of proteasome-mediated protein degradation was not affected, we examined Nrf2 and CyclinD1, which are rapidly degraded substrates of the proteasome. Immunoblot analysis revealed the degradation of Nrf1, but not Nrf2 or CyclinD1, was markedly attenuated by cholesterol. Collectively, these data show that cholesterol excess suppresses Nrf1 cleavage, degradation, and nuclear translocation.
To examine how cholesterol affects Nrf1 transcriptional activity, we initially used immortalized Nrf1
À/À , and Nrf2
MEFs expressing ARE-driven ''long half-life'' luciferase (AREiMEFs) as a transcriptional reporter assay. In this system, epoxomycin robustly stimulated luciferase activity in an Nrf1-dependent manner, but cholesterol had no effect ( Figure S3A ). In fact, in Nrf2 À/À ARE-iMEFs, which express luciferase exclusively under control of Nrf1, co-treatment with cholesterol blunted epoxomycin-induced luciferase activity ( Figure 3E ). This is consistent with its exclusion from the nucleus as observed by confocal imaging and cell fractionation (Figures 3A and 3B) . As a complementary approach, we produced Hek293A cells expressing upstream activating sequence (UAS) promoter-driven ''short half-life'' luciferase and a chimeric form of Nrf1 in which its DNA-binding domain was replaced with the UAS-targeting Gal4 DNA-binding domain (Nrf1-Gal4). In this system, cholesterol reduced baseline and epoxomycin-stimulated luciferase activity (Figures 3F and 3G) . To establish the relevance of this effect in vivo, we utilized a model in which proteasome subunits PsmB2 and PsmB5 mRNA were induced in mouse liver by the proteasome inhibitor bortezomib in an Nrf1-dependent manner ( Figure S3B ), as reported (Lee et al., 2013) . Importantly, feeding wild-type mice Chol-Diet suppressed induction of PsmB2 and PsmB5 in liver ( Figure 3H ). These data show that cholesterol excess prevents cleavage and release of Nrf1 from the ER and entrance into the nucleus, which thereby inhibits Nrf1 transcriptional activity. We postulated that Nrf1 senses cholesterol at the ER. Indeed, in wild-type primary MEFs the inhibition of cholesterol trafficking from plasma membrane to ER with 10 mM of an intracellular cholesterol transport inhibitor U18666A abolished the effect of cholesterol on Nrf1 ( Figure 4A ), whereas promoting cholesterol accumulation in the ER via inhibiting the ER-localized cholesterol-esterifying enzyme ACAT with 10 mg/mL of Sandoz 58035 enhanced the rise in Nrf1 ( Figure 4B ). This effect of ACAT inhibition was independent of oxysterol production, as it persisted in cholesterol 25-hydroxylase-deficient (CH25H
MEFs, which lack all other oxysterol-producing enzymes (Figure S4A) . Conversely, treatment with 40 mM of 25-hydroxycholesterol did not increase Nrf1 and instead blocked the effect of cholesterol on Nrf1 ( Figure S4B ). While this suggested Nrf1 senses cholesterol at the ER, we pursued a complementary approach by examining the effect of cholesterol on two rationally designed HA-tagged Nrf1 mutant variants expressed in Hepa 1-6 cells ( Figures 4C and 4D ). These were a mutant lacking amino acids 608-741 (DCT-HA), which removes the DNA binding domain but displays similar localization as Nrf1-HA, and a mutant lacking amino acids 1-103 (DNT-HA), which marks the natural cleavage site of Nrf1, producing an exclusively nuclear protein (Radhakrishnan et al., 2014) . Interestingly, DCT-HA and Nrf1-HA displayed equivalent responses to cholesterol but DNT-HA was completely unresponsive, supporting the notion that Nrf1 senses cholesterol at the ER. Following this evidence, we correlated the response of Nrf1 to rising ER cholesterol levels and compared this with SREBP2, which has a known cholesterol-response profile (Radhakrishnan et al., 2008) . Hepa 1-6 cells were treated with the cholesterol sequestering compound methyl-b-cyclodextrin (MbCD) or with 0 (control), 25, 50, 75, or 100 mM cholesterol for 4 hr, after which cells were collected for quantification of Nrf1 protein, SREBP2 activity, or ER membrane cholesterol level ( Figure 4E ). SREBP2 was most active when cholesterol was 16% below control levels and maximally reduced upon raising cholesterol a mere 4% above control levels. However, Nrf1 was not increased until ER cholesterol increased 89% above control level. Collectively, these data not only reveal Nrf1 senses cholesterol in the ER membrane but also a ''yin-yang'' relationship such that, while SREBP2 responds to a drop, Nrf1 responds to a rise in ER membrane cholesterol level ( Figure 4E ).
Since DNT-HA is cholesterol insensitive but transcriptionally active and DCT-HA is cholesterol sensitive but transcriptionally inactive, we utilized these mutants in vivo to examine whether cholesterol sensing or transcriptional regulation were necessary for Nrf1 to defend cholesterol homeostasis. Adenovirus expressing these constructs was delivered to Nrf1 flox and Nrf1 L-KO mice.
Mice were fed Reg-Diet or Chol-Diet for 1 week, after which liver tissues were collected for analysis (Figures 4F and 4G) . Expression of these genes did not alter cholesterol accumulation in Reg-Diet-fed mice. Under Chol-Diet, the cholesterol and cholesterol ester levels were similar in Nrf1 L-KO mice transduced with Nrf1-HA compared to Nrf1 flox control mice but elevated in Nrf1 L-KO mice transduced with LacZ, DNT-HA, or DCT-HA virus.
These biochemical patterns were apparent by H&E staining where only the reconstitution of Nrf1-HA reduced cholesterol (C) Immunoblots using lysates from Hepa 1-6 cells treated with 50 nM epoxomycin in the presence or absence of 100 mM cholesterol for 0-8 hr. Quantification of cleaved Nrf1 normalized to total Nrf1 and relative to time 0 shown at right (n = 4). *p < 0.05 treatment effect by two-way ANOVA.
(D) Immunoblots using lysates from wild-type primary MEFs treated with control or 100 mM cholesterol for 2 hr, after which 10 mg/mL of cycloheximide was added for indicated times. Quantification of bands normalized to Tubulin and relative to time 0 shown at right (n = 3). *p < 0.05 treatment effect by two-way ANOVA. accumulation. Overall, these findings demonstrated a mechanistically coupled response whereby Nrf1 must be capable of sensing ER cholesterol and regulating transcription to guard against cholesterol excess. The necessity for Nrf1 to regulate transcription in a manner inhibited by cholesterol led us to formulate a model in which nuclear Nrf1 represses a transcriptional program that defends against cholesterol accumulation ( Figure 5A ). In such a model, cholesterol excess would de-repress this program to engage an adaptive response, perhaps by interacting with other programs involving factors such as LXR or SREBP2. In the absence of Nrf1, there would be no impact on these factors as elevated cholesterol would be required to inhibit SREBP2 and oxysterols would be required to activate LXR. In contrast, the cholesterolinsensitive DNT-HA mutant would continue repressing these adaptive programs upon excess cholesterol exposure. To test this model, we delivered adenovirus that express LacZ, Nrf1-HA, or DNT-HA into primary hepatocytes isolated from Nrf1 L-KO mice. As a control, we delivered adenovirus that express LacZ to hepatocytes isolated from Nrf1 flox mice. The activity of DNT-HA was confirmed by a rise in known Nrf1 targeted proteasome subunits PsmB1, PsmB2, and PsmB5 (Figure S5A ). Cells were treated without or with cholesterol for 8 hr, after which the expression of LXR targets AbcA1, AbcG1, and Srebp1c, and SREBP2 targets Hmgcs1, Fdps, and LdlR were examined ( Figures 5B and S5B ). Strikingly, in cells expressing DNT-HA there was a modest decrease in Hmgcs1 and Fdps under control conditions, a marked rise in LdlR, and a major blunting of LXR targets following cholesterol treatment. Additionally, there was a blunted LXR response in DNT-HA-expressing cells following treatment with the LXR agonist GW3965 (Figure 5C ). Taken together, these data provide a mechanistic basis for the necessity of cholesterol sensing by Nrf1 to coordinate an adaptive response. Following this evidence, we examined whether Nrf1 senses cholesterol through a direct binding event. Using in vitro translation, we produced GFP-tagged full-length Nrf1 (Nrf1-GFP) and DNT mutant Nrf1 (DNT-GFP), and, as a positive control, we produced a GFP tagged sterol-sensing domain of Niemann-Pick C1 Like 1 (NPC1L1-GFP). Proteins were incubated with cholesterol in 0.1% Fos-Choline 13 at concentrations ranging from 0.1 to 6,000 nM, and interactions were measured using microscale thermophoresis. Nrf1-GFP interacted with cholesterol with an EC 50 of 28 ± 13 nM ( Figure 5D ) and the EC 50 of NPC1L1-GFP was 8 ± 4 nM ( Figure S5C) . Conversely, the DNT-GFP mutant did not bind cholesterol, revealing that Nrf1 binds cholesterol with an affinity comparable to NPC1L1 and dependent on its ER-membrane anchor. Continuing this investigation, we searched for a binding domain in Nrf1 by screening Hek 293A cells expressing truncation mutants. Cells were treated with or without cholesterol or epoxomycin, and immunoblots were performed on cell extracts. While cholesterol still regulated a mutant expressing amino acids 1-298, this effect was lost in a mutant expressing amino acids 1-124 ( Figure S5D ), suggesting a cholesterol-sensing domain resides between amino acids 125-298. Interestingly, within this region resides a putative cholesterol recognition amino acid consensus (CRAC) domain from amino acids 191-199 (Zhang et al., 2014) . Accordingly, we purified N-terminally His-tagged wild-type Nrf1-HA and a CRAC deletion (DCRAC-HA) mutant ( Figure S5E ), labeled proteins with a His-tag targeting fluorescent molecule, and used microscale thermophoresis to examine their binding properties ( Figure S5F ). While Nrf1-HA exhibited a binding curve with an EC 50 of 93 ± 44 nM, DCRAC-HA did not exhibit binding. Moreover, incubating Nrf1-HA and DCRAC-HA with 3 H-cholesterol resulted in direct evidence that Nrf1-HA binds cholesterol, whereas DCRAC-HA had substantially weaker binding ( Figure 5E ). We next examined the effect of CRAC domain deletion in cells. First, primary hepatocytes from Nrf1 L-KO mice were infected with adenovirus expressing LacZ or DCRAC-HA and treated without or with cholesterol for 8 hr, and the expression of target genes examined. The transcriptional activity of DCRAC-HA was confirmed by a rise in PsmB5, demonstrating this variant did not feature a general defect in its function ( Figure 5F ). The effect of cholesterol on AbcA1, AbcG1, and LdlR was dramatically diminished in cells expressing the DCRAC-HA protein, in a manner comparable to cells expressing DNT-HA (see Figures 5B and S5B ). In addition to this line of investigation, we also transfected plasmid DNA expressing Nrf1-HA, DCRAC-HA, or a control empty vector into Hepa 1-6 cells and examined the response of DCRAC-HA protein to cholesterol ( Figure 5G ). Interestingly, while wild-type Nrf1-HA protein levels increased upon cholesterol treatment, DCRAC-HA was completely unresponsive. Taken together, these findings indicate that Nrf1 senses cholesterol through direct binding, and this binding requires a CRAC domain residing at amino acids 191-199. We also investigated the specificity of Nrf1 for cholesterol by examining its capacity to bind structurally distinct sterols. Cholesterol was compared to campesterol and 27-hydroxycholesterol, which have additional methyl and hydroxyl groups in respective hydrocarbon tails, and with epicholesterol, an epimer of cholesterol containing a 3-a, instead of 3-b, hydroxyl group ( Figure S5G ). Remarkably, using microscale thermophoresis Nrf1 had an equivalent affinity for cholesterol as for campesterol and 27-hydroxycholesterol but a 10-fold lower affinity for epicholesterol ( Figure 5H ). As a complement, epicholesterol was not able to regulate Nrf1 in Hepa 1-6 cells ( Figure 5I ). Finally, using 400 nM of 3 H-cholesterol as labeled ligand in a competition assay ( Figure 5J) , unlabeled cholesterol had an IC 50 of 354 ± 64 nM (r = 0.93) whereas unlabeled epicholesterol had a substantially higher IC 50 of 6,883 ± 3,201 nM (r = 0.36), strongly demonstrating that Nrf1 has a specific affinity for the hydroxyl group of cholesterol.
Nrf1 Controls a Transcriptional Program Defending against Cholesterol Excess that Involves CD36
Our results indicate Nrf1 controls a transcriptional program that adapts cells to cholesterol as a means of averting stress and limiting cholesterol accumulation. But given our data showing that cholesterol induced repression of Nrf1 activity, the reason Nrf1-deficient livers develop severe problems was unclear. A possible mechanism could involve the aforementioned role of Nrf1 on proteasome regulation. However, in extracts isolated from livers of Nrf1 flox and Nrf1 L-KO mice fed regular diet or a cholesterol challenge, we did not observe differences in proteasome activity ( Figure S6A ). So we took an unbiased approach to delineate this program, utilizing RNA sequencing (RNA-seq) to systematically identify genes regulated by cholesterol in the presence or absence of Nrf1. The expression profiles of livers isolated from Nrf1 flox and Nrf1 L-KO mice fed Reg-Diet or following a 1-week Chol-Diet challenge were examined by using multidimensional scaling (MDS) analysis to visualize the profiles, and by comparing differentially expressed genes. MDS analysis showed the transcriptional changes induced by Chol-Diet were substantially greater in control Nrf1 flox mice, with 826 (8.12%) differentially expressed genes out of 10,174 detectable genes measured compared to only 93 (0.91%) in Nrf1 L-KO mice ( Figures  6A and S6B) , which demonstrated that Nrf1 L-KO mouse livers were relatively refractory to the transcriptional changes induced by a cholesterol challenge. As the mechanisms by which hepatocytes respond to cholesterol are well defined and known to be modulated by metabolic and inflammatory networks (Bensinger and Tontonoz, 2008; Fu et al., 2012; Russell, 2003; Steck and Lange, 2010) , we interrogated the expression profiles further to delineate whether Nrf1 defends hepatic cholesterol homeostasis by regulating these known processes. In agreement with a previous report (Hirotsu et al., 2012) , in Reg-Diet-fed mice, several genes involved in lipid metabolism displayed reduced expression in Nrf1 L-KO liver (Table S1 ). When comparing Chol-Diet to Reg-Diet, 790 differentially expressed genes were identified in livers of Nrf1 flox mice that were not identified in livers of Nrf1 L-KO mice, which we defined as genes regulated by cholesterol in an Nrf1-dependent manner (Table S2 ). Gene ontology analysis of this gene set using DAVID v.6.7 (Huang et al., 2009 ) revealed enriched clusters relating to the acute inflammatory response, lipid transport, and sterol metabolic process ( Figure 6B ). To validate this, we measured the expression of top-ranked genes in each cluster and additional genes involved in lipid metabolism and inflammation and performed hierarchical Euclidean distance analysis (Figure 6C ). In Nrf1 L-KO livers, the majority of genes related to inflammation were increased and clustered, whereas genes critical for sterol metabolism, such as the rate-limiting enzymes in the bile synthesis pathway, Cyp7a1 and Cyp7b1, were decreased. These data suggest that Nrf1 suppresses inflammation and promotes cholesterol excretion.
In considering pathways underlying the detrimental outcome of Nrf1 deficiency, we noted that CD36 was singly grouped and elevated in Nrf1 deficiency ( Figure 6C ). CD36 is a scavenger receptor implicated in fatty liver disease (Hui et al., 2015; Wilson et al., 2016) and highly integrated with metabolism, inflammation, and regulation of stress kinases such as JNK (Silverstein and Febbraio, 2009 ). Interestingly, inflammatory and JNK signaling can suppress Cyp7a1 expression and activity (Chen et al., 2012; Li et al., 2006) , whereas normal Cyp7a1 activity protects the liver against inflammation and cholesterol accumulation (Liu et al., 2016; Russell, 2003) . Therefore, we investigated the impact of CD36 as a putative Nrf1 target. We measured the protein levels of CD36 and phosphorylated JNK, comparing livers of Nrf1 L-KO mice to those of Nrf1 flox mice after a 2-day Chol-Diet challenge, followed by 2 days of Reg-Diet (Chol-toReg). Protein levels of CD36 and phosphorylated JNK were elevated in livers of Nrf1 L-KO mice challenged with Chol-Diet, and remained elevated during the Chol-to-Reg phase (Figure 6D) . In gene expression analysis from this experiment lack of Nrf1 resulted in elevated CD36 mRNA level, including in livers of Reg-Diet-fed mice ( Figure 6E ). The cholesterol synthesis genes Hmgcs1 and Fdps were unaltered, and cholesterol export genes AbcG5 and AbcG8 were only slightly reduced in the Cholto-Reg phase. Strikingly, while Cyp7a1 was similar between genotypes of Reg-Diet-fed mice, Chol-Diet feeding sharply reduced Cyp7a1 expression in livers of Nrf1 L-KO mice, but not in Nrf1 flox mice. Similarly, Cyp7b1 mRNA was reduced in livers of Nrf1 L-KO mice. These findings show the regulation of CD36, Cyp7a1, and Cyp7b1 expression as well as JNK phosphorylation is altered in Nrf1 deficiency. To examine whether Nrf1 directly regulates CD36 expression, we performed chromatin immunoprecipitation (ChIP)-qPCR analysis of fixed chromatin samples collected from mouse livers expressing LacZ control or Nrf1-HA ( Figure 6F ). Targeted ChIP-qPCR of ARE sites located in the CD36 promoter (Maruyama et al., 2008) revealed two sites enriched by anti-HA immunoprecipitation from livers expressing Nrf1-HA, but not in controls, thus demonstrating in vivo that Nrf1 directly binds specific ARE sites located in the CD36 promoter. As confirmation that Nrf1 regulates CD36 expression, infection of isolated Nrf1-deficient primary hepatocytes with adenovirus expressing Nrf1-HA or DCRAC-HA resulted in a reduction in CD36 mRNA levels relative to cells infected with LacZ-expressing adenovirus ( Figure 6G ). Interestingly, cholesterol treatment increased CD36 levels in cells expressing Nrf1-HA but not in cells expressing DCRAC-HA or LacZ ( Figure 6H ). Taken together, these data indicate that Nrf1 regulates CD36 expression in hepatocytes in a cholesterol-sensitive manner.
To evaluate a causal role for CD36 in contributing to cholesterol accumulation in livers of Nrf1-deficient mice, we used a cell-impermeable fatty acid analog called sulfosuccinimidyl oleate (SSO), which has a selective inhibitory effect on CD36 (Coort et al., 2002; Kuda et al., 2013) . We reasoned that if targeting CD36 by Nrf1 comprises a part of its adaptive program, blocking CD36 activity with SSO should ameliorate detrimental aspects of hepatic Nrf1 deficiency. SSO (10 mg/kg) or vehicle was administered daily to Chol-Diet-fed mice for 10 days. Remarkably, in livers of Nrf1 L-KO mice fed Chol-Diet, SSO restored JNK phosphorylation level, Cyp7a1, Cyp7b1, Ccl2, and CD68 mRNA levels, cholesterol and cholesterol ester levels, and the H&E-stained tissue appearance to those of livers from Chol-Diet-fed Nrf1 flox mice ( Figures 7A-7C and S7A ). Moreover, while there was a marked induction of liver enzymes AST and ALT in the serum of Nrf1 L-KO mice fed Chol-Diet, indicating the presence of liver toxicity, this effect was also mitigated by SSO ( Figure 7D 
DISCUSSION
In life, there is a fundamental necessity to couple nutrient acquisition, storage, and utilization with adaptive systems limiting the damage arising from highly reactive biochemical processes. Understanding these systems is essential to curb health problems emerging from chronic metabolic diseases with strong nutritional underpinnings (Hotamisligil, 2017) . Our study originated with a premise that the ER serves as a platform for adaptive systems defending metabolic homeostasis. This seems necessary, given the diverse functions of ER, which must be processive and tunable as well as its high susceptibility to energetic or immunometabolic stresses (Hotamisligil, 2010) . We considered the challenges imposed on the ER by excess cholesterol and identified Nrf1 as a critical mitigating factor. Our study demonstrates for the first time that cholesterol regulates Nrf1 localization, processing, turnover, and transcriptional activity, and that Nrf1 deficiency disrupts cellular defenses against cholesterol excess. We show that Nrf1 drives a mechanistically coupled response, the pillars of which involve inflammation, lipid transport, and sterol metabolism. As such, our findings reveal a powerful immunometabolic adaptive system that supports cellular function, organ integrity, and, by extension, systemic metabolic homeostasis.
In delineating how Nrf1 coordinates this response, we identified two mechanistic facets. First, we identify CD36 as an important player directly targeted by Nrf1. Interestingly, CD36 in the See also Figure S6 and Tables S1 and S2 . (legend continued on next page) liver has been causally linked to fatty liver disease and aberrant glycemic control (Hui et al., 2015; Wilson et al., 2016) , but its role in hepatic cholesterol metabolism is poorly understood. As CD36 facilitates lipid uptake and impacts inflammation through forming signaling complexes (Silverstein and Febbraio, 2009 ), Nrf1 might engage this regulatory link upon cholesterol exposure to trigger immunometabolic responses meant to transiently counteract the incurring stress. Such a response might enhance the influx of fatty acids for cholesterol esterification or the production of phospholipid-rich micelles required in bile for solubilizing excreted cholesterol. Alternatively, CD36 might engage stress signals that transiently halt metabolic circuits and warn the cell of the impending problem cholesterol might pose to ER metabolic functions. In Nrf1 deficiency, however, CD36 level is constitutively increased resulting in chronic inflammatory signaling, a signature feature of metaflammation and chronic metabolic diseases (Hotamisligil, 2017) . In liver, this causes hyper-activation of JNK, which downregulates bile synthesis, resulting in diminished cholesterol excretion, hepatic cholesterol accumulation, and fatty liver disease. The second mechanistic facet we show is that Nrf1 must sense cholesterol to confer protective actions. Indeed, constitutively active but cholesterolinsensitive Nrf1 could not rescue Nrf1-deficient livers. This likely relates to the interference of nuclear Nrf1 on LXR, a feature consistent with the role of LXR as a multifaceted countermeasure against excess cholesterol, but further studies are needed to delineate the nature of this potentially intricate network. A key underlying mechanism is that Nrf1 senses cholesterol at the ER through direct binding to a CRAC domain at amino acids 191-199. Interestingly, this is near a PEST domain extending into the ER lumen but can bury within the ER membrane (Zhang et al., 2014) . If rising cholesterol were to drive this event, it would explain how cholesterol represses Nrf1 turnover. It is remarkable that Nrf1 has a 10-fold higher affinity for cholesterol than its 3-hydroxyl epimer, as other cholesterol sensors such as SCAP and ACAT exhibit similarities and differences in ligand selectivity (Liu et al., 2005; Radhakrishnan et al., 2004) . A major distinction is how cholesterol orients, as the hydroxyl positions near phospholipid head groups. We surmise that, as ER cholesterol rises, it will exceed the membrane carrying capacity resulting in a greater tendency to escape (Steck and Lange, 2010) , at which point the hydroxyl group will more frequently project out and bind to the Nrf1 CRAC domain (see illustrated model in Figure S7B) . Consistent with this scenario, the Nrf1 response occurred when cholesterol elevated above homeostatic levels, suggesting Nrf1 is precisely poised to sense cholesterol in the ER when it reaches a ''stressful'' threshold. Within normal metabolic and inflammatory constraints, we envision this function of Nrf1 evolved as an acute, tunable, and moderate response that briefly alters metabolic and inflammatory circuits until homeostasis is restored, at which point Nrf1 would return to repressing CD36 and LXR activity (see illustrated model in Figure 7F ). This might ensure LXR is disengaged after abatement of a cholesterol challenge and suppress LXR in cells exposed to oxysterols but not an actual rise in cholesterol in order to protect against excess synthesis of lipids or difficult to fold proteins such as AbcA1. Interestingly, this function combined with the function of Nrf1 on the proteasome suggests that Nrf1 operates like a toggle in which its activation supports fatty acid and protein homeostasis, and its suppression supports cholesterol homeostasis, making Nrf1 highly integrated with the core metabolic functions of the ER.
Importantly, our study might resolve a gap in current models describing how cells achieve cholesterol homeostasis. That is, while the ER has an especially low cholesterol composition, which must remain stable to maintain the activity of ER-resident enzymes (Maxfield and Tabas, 2005) , the mechanistic constraints supporting this system are poorly understood. While ACAT contributes to this process by producing cholesterol esters, we show here that Nrf1 couples to a broad adaptive program, which guards cellular integrity. As cholesterol is fundamental to virtually all aspects of mammalian biology (Tabas, 2002) , it is an appealing teleonomic notion that Nrf1 and SREBP2 co-evolved as a yin-yang counterbalance to stabilize ER-resident metabolic activity ( Figure 4E) ; while both are ER membrane spanning proteins, SREBP2 promotes cholesterol production, whereas Nrf1 promotes cholesterol removal.
Finally, as full-length murine Nrf1 is a ubiquitously expressed 741 amino acid protein that is 97% identical to the human ortholog (McKie et al., 1995) , a corollary of our discovery is that it may have broad physiological and therapeutic implications. Indeed, pharmacological manipulation of Nrf1 might lead to a new, powerful unifying therapeutic avenue for mitigating the toxic effects of excess cholesterol to treat a multitude of human diseases.
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UAS-driven luciferase from Promega and a vector expressing a chimeric protein encoding amino acids 1-607 of Nrf1 and the DNA binding domain of Gal4 (Nrf1-Gal4) under control of the thymidine kinase promoter. Nrf1-Gal4 was encoded in place of Gluc in the pTK Gluc vector from NEB. After transfection, cells were selected with 500 mg/ml G418 and 100 mg/ml Hygromycin B Gold for at least 2 weeks. Primary hepatocyte isolation and infection Hepatocytes were isolated from liver of indicated mice and cultured in William's Media E, 5% CCS, L-Glutamine, and antibiotics. The day after isolation, cells were infected with indicated adenovirus at a multiplicity of infection (MOI) of 150. After 6-8 hr, cells received fresh media. Cells were treated approximately 24 hr later.
METHOD DETAILS
Animal infection, injection, and tissue collection For adenoviral expression experiments, randomly assigned age matched mice were infected with 1*10 9 phage forming units and necropsy was done 9-14 days later. Sulfosuccinimidyl oleate (10 mg/kg in 10% v/v DMSO in PBS, Bortezomib (5 mg/kg in 10% v/v DMSO in PBS) or vehicle control (10% v/v DMSO in PBS) were injected in the intraperitoneum. Mice were anesthetized with 300 mg/kg ketamine and 30 mg/kg xylazine in PBS, blood was collected via cardiac puncture and then mice were perfused with PBS containing 10 mU/ml heparin. In all related studies, liver was harvested and immediately snap-frozen in liquid nitrogen and stored at À80 C. Serum was collected from blood centrifuged at 8000 g, 4 C for 10 min.
In vivo cholesterol excretion from the liver to the feces To measure cholesterol excreted into fecal bile, restrained mice received tail vein injections of 3 H-labeled cholesterol-oleate in recombinant lipoprotein at a dose of 3 mCi / 30 g bodyweight. Approximately 16 hr later, total feces were collected and radioactivity measured.
Solubilizing cholesterol
In studies on cultured cells treated with cholesterol, we first solubilized dry cholesterol powder in 100% ethanol at 65 C and then added this to methyl-b-cyclodextrin (MbCD) in water at a concentration of 5 mM cholesterol to 42 mg/ml MbCD, which was then cooled and sterile filtered. Cells were treated by adding the cholesterol complex to media at a concentration of 100 mM (or otherwise indicated). This method causes cells to accumulate cholesterol because the stoichiometric capacity of MbCD to complex with cholesterol is near maximal. As such, in cell culture media there is a high tendency for cholesterol to transfer into cellular membranes, at which point it circulates through the normal cellular cholesterol pools. Conversely, cells treated with only MbCD (no cholesterol) results in the opposite effect such that cholesterol leaves cell membranes to complex with MbCD. We used this method to deplete ER membrane cholesterol levels in cells and activate SREBP2, as shown in Figure 4E .
In binding studies using cholesterol or other sterols, the dry sterol powder was mixed with binding buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT) containing micelles of 0.1% or 0.5% fos-choline 13. Upon applying to a vortex this by itself solubilized the sterol at room temperature. The mixture was left to incubate at room temperature for at least 2 hr to distribute equally among the micelles.
Binding studies
To produce protein for binding studies, the indicated proteins were generated from encoded cDNAs in a pT7CFE1-NHis-GST-CHA vector using the 1-Step Human High-Yield Mini in vitro translation (IVT) kit. In studies utilizing microscale thermophoresis (MST), GFP tagged protein samples were diluted at least 10 times in binding buffer with 0.1% fos-choline until achievement of optimal fluorescence units, and then mixed with cholesterol in binding buffer at indicated concentrations at room temperature. Fluorescence was determined in a thermal gradient generated by a Monolith NT.115 from NanoTemper Technologies and the data analyzed by MOAffinityAnalysis v2.1.23333. In studies on non-GFP tagged protein, samples were diluted in binding buffer with 0.1% or 0.5% fos-choline 13, as indicated, and purified with cobalt chelating resin. Chelated samples were washed by rotating for 5 min at 4 C in 5 volumes of binding buffer for 4 consecutive times. Protein samples were then eluted in 2 volumes of binding buffer containing 250 mM imidazole that was mixed for 5 min at 30 C in a thermomixer at 1200 RPM for 3 consecutive times. Then, samples were added to 0.5 mL Pierce Concentrator tubes (30 KDa cut-off) for 6 rounds of 10x concentration to dilute imidazole to at least less than 1 mM. Aliquots of these protein samples underwent electrophoresis and Coomassie staining. The protein concentration was determined by comparing sample density to an albumin standard curve. Protein samples were then labeled, using the Monolith His-Tag Labeling Kit Red-tris-NTA from NanoTemper technologies and MST performed at a concentration of 25 nM.
In the radioactive binding assay, 2 pmol (20 nM final concentration) of the indicated purified protein in 100 mL binding buffer with 0.1% fos-choline 13 was incubated with 400 nM 3 H-labeled cholesterol either alone or with unlabelled cholesterol or unlabelled epicholesterol at concentrations ranging from 2 nM to 80,000 nM for 4 hr. Protein samples were then isolated with colbalt chelating resin, washed by rotating for 5 min at room temperature in 5 volumes of binding buffer 4 consecutive times, and eluted in 5 volumes of binding buffer with 0.1% fos-choline 13 containing 250 mM imidazole, which was mixed for 20 min at 37 C in a thermomixer at 1200 RPM. Eluates were transferred to tubes containing EcoScint and radioactivity measured.
from Bio-Rad, blocked in TBST containing 5% milk, and then incubated overnight with primary antibodies in TBST containing 0.5% milk at 4 C with shaking. After washing 3x for 5 min with TBST containing 0.5% milk, anti-rabbit or anti-mouse HRP-conjugated antibody from Santa Cruz Biotechnologies were applied for 1-2 hr in TBST containing 0.5% milk at room temperature. After washing 3x for 5 min with TBST containing 0.5% milk, membranes were incubated with Super Signal West Femto Maximum Sensitivity Substrate from ThermoFisher Scientific to generate a chemiluminescent signal detected with a FluorChem M imager from ProteinSimple. Digital images were analyzed with AlphaView software or ImageJ.
Systematic Lipid analyses in liver and MEFs
Liver studies measuring only total cholesterol and unesterified cholesterol were performed with approximately 50-150 mg tissue samples using the Cholesterol Quantitation kit from Sigma. Systematic lipid analysis, which included absolute quantitation of all major classes of complex lipids was performed using the TrueMass Lipid Profiling Platform, and unesterified cholesterol measurements were performed by Lipomics Technologies Incorporated, a part of Metabolon.
Viability and luciferase assays Viability assay of 1 MEFs was done using the CytoTox-ONE Homogeneous Membrane Integrity Assay kit from Promega. For each luciferase expressing cell line, the luciferase assay was done using the Luciferase Assay System from Promega.
Serum analyses
Liver transaminases were determined using the Lipid Panel Plus Piccolo Xpress clinical chemistry platform (Abaxis).
RNA sequencing (RNaseq) analysis
Total RNA samples from liver were enriched in mRNAs, and then processed and barcoded at the Harvard Biopolymers Facility. Sequencing was performed using a HiSeq 2500 System from Illumina. FastQ raw read data files were then analyzed utilizing the Tuxedo suite tools available at the Broad institute's GenePattern server.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were expressed as Mean ± Standard Error of the Mean (SEM) or as box and whisker plots with min and max values. Significance was defined as p < 0.05 determined using the two-tailed, unpaired Student's t test, one-way analysis of variance (ANOVA) or two-way ANOVA as indicated in the figure legends. Sidak's test was used for multiple comparisons. Data analysis was performed using GraphPad Prism software version 7.0.
Study approval
All experimental procedures were approved by the Harvard T.H. Chan School of Public Health Institutional Animal Care and Use Committee. Randomly assigned littermates were used when comparing Nrf1 flox to Nrf1 L-KO mice.
DATA AVAILABILITY
The raw data has been deposited in the Mendeley repository (https://doi.org/10.17632/knmfx9t732.2). The RNA-seq raw data files have been deposited with NCBI with GEO accession number GEO: GSE103949.
Supplemental Figures
Reg , Nrf1 +/À mice fed Reg-Diet or one week with Chol-Diet. Quantitation of P-JNK normalized by total JNK shown below (n = 3). *p < 0.05 by Student's t test. H) Nrf1 flox or Nrf1 L-KO mice were fed Reg-Diet or Chol-Diet for one or four weeks (n = 8-12) and liver weight and body weight measured. *p < 0.05 by Student's t test. Data in graphs are mean ± SEM. AU, arbitrary units; g, gram; Poly I:C, Polyinosinic:polycytidylic acid; t-BHQ, tertButylhydroquinone; TNFa, Tumor necrosis factor a; FL., full length; CL., cleaved; h, hours.
